These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33387496)

  • 21. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
    Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Available evidence on re-irradiation with stereotactic ablative radiotherapy following high-dose previous thoracic radiotherapy for lung malignancies.
    De Bari B; Filippi AR; Mazzola R; Bonomo P; Trovò M; Livi L; Alongi F
    Cancer Treat Rev; 2015 Jun; 41(6):511-8. PubMed ID: 25913714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stereotactic body radiotherapy for oligometastatic lung tumors.
    Norihisa Y; Nagata Y; Takayama K; Matsuo Y; Sakamoto T; Sakamoto M; Mizowaki T; Yano S; Hiraoka M
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):398-403. PubMed ID: 18374506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcomes of stereotactic brain and/or body radiotherapy for patients with oligometastatic lesions.
    Inoue T; Katoh N; Aoyama H; Onimaru R; Taguchi H; Onodera S; Yamaguchi S; Shirato H
    Jpn J Clin Oncol; 2010 Aug; 40(8):788-94. PubMed ID: 20406944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.
    Juan O; Popat S
    Clin Lung Cancer; 2017 Nov; 18(6):595-606. PubMed ID: 28377206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Organs at risk in lung SBRT.
    De Rose F; Franceschini D; Reggiori G; Stravato A; Navarria P; Ascolese AM; Tomatis S; Mancosu P; Scorsetti M
    Phys Med; 2017 Dec; 44():131-138. PubMed ID: 28433508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stereotactic radiotherapy in oligometastatic cancer.
    Kennedy TAC; Corkum MT; Louie AV
    Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S16. PubMed ID: 28917254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Video-assisted thoracoscopic lobectomy is associated with greater recurrence-free survival than stereotactic body radiotherapy for clinical stage I lung cancer.
    Cornwell LD; Echeverria AE; Samuelian J; Mayor J; Casal RF; Bakaeen FG; Omer S; Preventza O; Mai W; Chen G; Simpson KH; Moghanaki D; Zhu AW
    J Thorac Cardiovasc Surg; 2018 Jan; 155(1):395-402. PubMed ID: 28888379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The course of lung oligometastatic colorectal cancer may be a reflection of selection for treatment rather than an effect of stereotactic body radiotherapy.
    Macbeth F; Treasure T
    Strahlenther Onkol; 2021 Jan; 197(1):74-75. PubMed ID: 33242138
    [No Abstract]   [Full Text] [Related]  

  • 30. Pulmonary oligometastases: metastasectomy or stereotactic ablative radiotherapy?
    Widder J; Klinkenberg TJ; Ubbels JF; Wiegman EM; Groen HJ; Langendijk JA
    Radiother Oncol; 2013 Jun; 107(3):409-13. PubMed ID: 23773410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pulmonary function and quality of life after VMAT-based stereotactic ablative radiotherapy for early stage inoperable NSCLC: a prospective study.
    Ferrero C; Badellino S; Filippi AR; Focaraccio L; Giaj Levra M; Levis M; Moretto F; Torchio R; Ricardi U; Novello S
    Lung Cancer; 2015 Sep; 89(3):350-6. PubMed ID: 26164208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reply to: The course of lung oligometastatic colorectal cancer may be a reflection of selection for treatment rather than an effect of stereotactic body radiotherapy.
    Nicosia L; Cuccia F; Alongi F
    Strahlenther Onkol; 2021 Jan; 197(1):76-78. PubMed ID: 33242139
    [No Abstract]   [Full Text] [Related]  

  • 33. Stereotactic ablative body radiation therapy for tumors in the lung in octogenarians: a retrospective single institution study.
    Cannon NA; Iyengar P; Choy H; Timmerman R; Meyer J
    BMC Cancer; 2014 Dec; 14():971. PubMed ID: 25518879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving outcomes for high-risk patients with early-stage non-small-cell lung cancer: insights from population-based data and the role of stereotactic ablative radiotherapy.
    Palma DA; Senan S
    Clin Lung Cancer; 2013 Jan; 14(1):1-5. PubMed ID: 22846581
    [No Abstract]   [Full Text] [Related]  

  • 35. Novel case of nephrocolic fistula secondary to stereotactic ablative body radiotherapy for clear cell renal cell carcinoma.
    Brinded A; Tay YK; Woods R
    ANZ J Surg; 2020 Sep; 90(9):1800-1801. PubMed ID: 31989764
    [No Abstract]   [Full Text] [Related]  

  • 36. [Oligometastatic disease, a new concept: stereotactic irradiation for lung metastases. Literature review].
    Hatime M; Elmorabit B; Elkhoti Y; Touch S; Tanguy R; Mornex F
    Cancer Radiother; 2012 Sep; 16(5-6):351-7. PubMed ID: 22921980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.
    Kissel M; Martel-Lafay I; Lequesne J; Faivre JC; Le Péchoux C; Stefan D; Barraux V; Loiseau C; Grellard JM; Danhier S; Lerouge D; Chouaid C; Gervais R; Thariat J
    BMC Cancer; 2019 Dec; 19(1):1237. PubMed ID: 31856742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Stereotactic ablative irradiation for lung cancer].
    Antoni D; Srour I; Noël G; Mornex F
    Cancer Radiother; 2014; 18(4):297-307. PubMed ID: 24907006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stereotactic ablative therapy and the central chest: in regard to Oskan.
    Lo SS; Huang Z; Yuh WT; Mayr NA
    Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):1143. PubMed ID: 25035225
    [No Abstract]   [Full Text] [Related]  

  • 40. A phase I dose-escalation trial of stereotactic ablative body radiotherapy for non-spine bone and lymph node metastases (DESTROY-trial).
    Mercier C; Dirix P; Meijnders P; Vermeulen P; Van Laere S; Debois H; Huget P; Verellen D
    Radiat Oncol; 2018 Aug; 13(1):152. PubMed ID: 30126440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.